U.S. Markets closed

Bayer seeks wider use for eye drug Eylea in Europe

FRANKFURT, Nov 7 (Reuters) - German drugmaker Bayer said it filed for marketing approval in Europe for the use of eye drug Eylea as a treatment of diabetic macular oedema.

Bayer has said it expects Eylea, also known as VEGF Trap-Eye, to generate more than 1 billion euros ($1.35 billion) in peak annual sales.

The injection, which Bayer is co-developing with Regeneron , is already approved for other eye diseases.